NTRA Natera Inc
1,721
$105.12
$9.57
(10.02%)
| Watchers | 1,721 |
| 52-Wk Low | $36.90 |
| 52-Wk High | $98.82 |
| Market Cap | $11.68B |
| Volume | 2.33M |
| 52-Wk High | $98.82 |
| 52-Wk Low | $36.90 |
Why Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving PremarketBenzinga • about 6 hours ago
read more...
Share to Feed
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Recent Strategic and Financial...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability of its personalized and...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 2024, after the market close on...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at a critical time for the...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publication of more than 200...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting the use of the Prospera Kidney...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasing the ability of the Prospera...
Natera (NASDAQ:NTRA - Get Free Report) was upgraded by equities research analysts at Sanford C. Bernstein from a "market perform" rating to an "outperform" rating in a report issued on Friday...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Association of Urology (EAU) Congress...